Replies to post #15318 on Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

It's possible. It depends on 1) how quickly the phase 1 trial enrolls, 2) what the safety profile is, 3) whether the fda accepts a phase 2 registration trial and 4) if they do accept a pivotal P2, what the trial design is (eg sufficient crizotinib failures to power the trial). 2014 is much more likely, imo, which gives us all (well, some of us anyway) something to look forward to, lol.